In particular, elevated activation of the KEAP1/NRF2/SLC7A11 axis of glutathione synthesis has been detected in various cancer cells and patients with breast cancer, bladder cancer, gastric carcinoma, glioma, and melanoma; this mechanism plays a major role in the resistance of cancer cells to cancer therapies [110,111]. This evidence concerns the gene SLC7A11 and central nervous system cancer.